Biocentury: Regeneron Using Interleukin Antibody Receptors for Asthma Medication

An estimated 25 million Americans suffer from Asthma, but current medications such as inhalers have been deemed ineffective for 10-20% of its users. Regneron (REGN) and Sanofi (SAN) have partnered to crease a new Asthma drug, Dupilumab. In their most recent Phase IIa trial, 87% of patients showed less asthma attacks or other symptomatic outbreaks compared with those patients receiving the placebo. The New England Journal of Medicine stated it is “too early to tell if this therapy will be of clinical value, though it is probably on the right track.” The Phase IIb trial is expected to begin mid 2013 and at this rate market release is expected within the next 2-3 years.

View the full article here (https://www.biocentury.com/dailynews/topstory/2013-05-21/dupilumab-meets-in-phase-iia-asthma-trial).

 

The comments are closed.